Your contact persons

CHEPLAPHARM Arzneimittel GmbH

CHEPLAPHARM successfully closes acquisition of Zyprexa® portfolio

Following signing on April 21, 2023, CHEPLAPHARM has successfully closed the acquisition of the worldwide[1] commercial rights for Zyprexa® from Eli Lilly and Company. Zyprexa®, with its API Olanzapine, is an established treatment of schizophrenia and bipolar disorders, has a broad patient base worldwide and is well-positioned in respective markets. CHEPLAPHARM is acquiring the entire Zyprexa® product portfolio, including, among others, the tablet and intramuscular dosage forms. With a total purchase price[2] of $1.351bn US, this is the largest transaction in the history of CHEPLAPHARM to date.

As the world's leading acquirer of originator brands from research-based pharma companies, CHEPLAPHARM has built up a broadly diversified portfolio of established medicines over the past 20 years. Now, Zyprexa®, another important, globally established medicine, is being added to the Company's product portfolio. Following the successful consummation of the acquisition, CHEPLAPHARM is now continuing to work in close coordination with Lilly to ensure the rapid and smooth integration of the products into its own established structures. “With our global and diversified network of distribution partners, suppliers and contract manufacturers, we can ensure a seamless transition in supply and the continued availability of Zyprexa® for patients around the world”, says Edeltraud Lafer, CEO of CHEPLAPHARM.

[1] Excluding South Korea.
[2] Excluding up to $50m US milestone payment (payable in two tranches).

Back to topexpand_less